Overview

QUILT-3.049: NANT Triple Negative Breast Cancer (TNBC) Vaccine: Combination Immunotherapy in Subjects With TNBC Who Have Progressed on or After Anthracycline-based Chemotherapy

Status:
Withdrawn

Trial end date:
2019-03-01

Target enrollment:

Participant gender:

Summary

This is a phase 1b/2 study to evaluate the safety and efficacy of metronomic combination therapy in subjects with metastatic or unresectable TNBC who have progressed on or after anthracycline-based chemotherapy or who have refused anthracycline-based chemotherapy.

Phase:

Phase 1/Phase 2

Details

Lead Sponsor:

ImmunityBio, Inc.
NantCell, Inc.

Treatments:

Avelumab
Bevacizumab
Capecitabine
Cisplatin
Cyclophosphamide
Fluorouracil
Leucovorin
Paclitaxel
Vaccines